Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial-Reference-Cited by-同舟云学术

Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial

Published:2017-08-09 Issue:10 Volume:24 Page:734-740
ISSN:1672-0415
Container-title:Chinese Journal of Integrative Medicine
language:en
Short-container-title:Chin. J. Integr. Med.

Author:

Yang Xiao-bing,Chai Xiao-shu,Wu Wan-yin,Long Shun-qin,Deng Hong,Pan Zong-qi,He Wen-feng,Zhou Yu-shu,Liao Gui-ya,Xiao Shu-jing

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Complementary and alternative medicine,General Medicine

Link

http://link.springer.com/article/10.1007/s11655-017-2819-8/fulltext.html

Reference40 articles.

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010;60:277–300.

2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.

3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367–1380.

4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase ? trial of gefi tinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 2003;21:2237–2246.

5. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149–2158.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma;Journal of Ethnopharmacology;2024-01

2. Fuzheng Kang-Ai decoction increases the sensitivity of Gefitinib via inducing Non-Small Cell Lung Cancer ferroptosis through AMPK/SLC7A11 pathway;2023-10-18

3. Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway;Journal of Ethnopharmacology;2023-10

4. Fuzheng Kang-Ai inhibits NSCLC cell proliferation via regulating hsa_circ_0048091/hsa-miR-378g/ARRDC3 pathway;Phytomedicine;2023-06

5. Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada;Current Oncology;2022-10-26